GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CinCor Pharma Inc (NAS:CINC) » Definitions » Net Cash per Share

CinCor Pharma (CinCor Pharma) Net Cash per Share : $11.71 (As of Sep. 2022)


View and export this data going back to 2022. Start your Free Trial

What is CinCor Pharma Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). CinCor Pharma's Net Cash per Share for the quarter that ended in Sep. 2022 was $11.71.

The historical rank and industry rank for CinCor Pharma's Net Cash per Share or its related term are showing as below:

CINC' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.14   Med: 2.48   Max: 2.8
Current: 2.48

During the past 3 years, the highest Price-to-Net-Cash Ratio of CinCor Pharma was 2.80. The lowest was 2.14. And the median was 2.48.

CINC's Price-to-Net-Cash is not ranked
in the Biotechnology industry.
Industry Median: 4.04 vs CINC: 2.48

CinCor Pharma Net Cash per Share Historical Data

The historical data trend for CinCor Pharma's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CinCor Pharma Net Cash per Share Chart

CinCor Pharma Annual Data
Trend Dec19 Dec20 Dec21
Net Cash per Share
-0.23 -0.81 -1.93

CinCor Pharma Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.42 -1.93 8.18 7.61 11.71

Competitive Comparison of CinCor Pharma's Net Cash per Share

For the Biotechnology subindustry, CinCor Pharma's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CinCor Pharma's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CinCor Pharma's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where CinCor Pharma's Price-to-Net-Cash falls into.



CinCor Pharma Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

CinCor Pharma's Net Cash per Share for the fiscal year that ended in Dec. 2021 is calculated as

Net Cash per Share (A: Dec. 2021 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(136.606-204.824-0)/35.4191
=-1.93

CinCor Pharma's Net Cash per Share for the quarter that ended in Sep. 2022 is calculated as

Net Cash per Share (Q: Sep. 2022 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(522.497-10.182-0)/43.7643
=11.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CinCor Pharma  (NAS:CINC) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


CinCor Pharma Net Cash per Share Related Terms

Thank you for viewing the detailed overview of CinCor Pharma's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


CinCor Pharma (CinCor Pharma) Business Description

Traded in Other Exchanges
N/A
Address
200 Clarendon Street, 6th Floor, Boston, MA, USA, 02116
CinCor Pharma Inc is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases.
Executives
Sofinnova Management X-a, L.l.c. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
James Healy director, 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Michael Wayne Kalb officer: EVP & Chief Financial Officer 24 LUCILLE LANE, DIX HILLS NY 11746
5am Opportunities Ii (gp), Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISO CA 94107
5am Opportunities Ii, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Vi, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Partners Sas Sofinnova 10 percent owner 17 RUE DE SERENE, PARIS I0 75008
Maha Katabi 10 percent owner SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Sofinnova Venture Partners X, L.p. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Sofinnova Management X, L.l.c. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
General Atlantic Genpar (bermuda), L.p. 10 percent owner C/O GENERAL ATLANTIC SERVICE COMPANY,LLC, 55 EAST 52ND ST. 32ND FLOOR, NEW YORK NY 10055
General Atlantic, L.p. 10 percent owner 55 EAST 52ND STREET, 33RD FLOOR, NEW YORK NY 10055
Mason Freeman officer: EVP Clinical Development C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Mary Theresa Coelho officer: EVP CFO & Chief BD Officer 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Garidel Marc De director, officer: Chief Executive Officer C/O CINCOR PHARMA, INC., 200 CLARENDON STREET, 6TH FLOOR, BOSTON MA 02116

CinCor Pharma (CinCor Pharma) Headlines

From GuruFocus

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CINC, ALBO, PAYA, QUMU

By Stock market mentor Stock market mentor 01-29-2023